HC Wainwright Trims Scilex (NASDAQ:SCLX) Target Price to $7.00

Scilex (NASDAQ:SCLX) had its target price lowered by HC Wainwright from $8.00 to $7.00 in a report issued on Thursday morning, Benzinga reports. The firm currently has a buy rating on the stock. HC Wainwright also issued estimates for Scilex’s Q4 2025 earnings at ($0.01) EPS.

Scilex Stock Up 3.7 %

Shares of Scilex stock opened at $1.13 on Thursday. The stock’s fifty day moving average is $1.15 and its two-hundred day moving average is $1.40. Scilex has a 52 week low of $0.73 and a 52 week high of $8.30. The company has a market capitalization of $204.74 million, a PE ratio of -0.86 and a beta of 0.91.

Scilex (NASDAQ:SCLX) last posted its quarterly earnings results on Monday, March 11th. The company reported ($0.25) EPS for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.04). The firm had revenue of $13.46 million for the quarter, compared to analysts’ expectations of $11.43 million. As a group, research analysts anticipate that Scilex will post -0.63 earnings per share for the current year.

Insider Activity

In other news, Director Jay Chun acquired 57,500 shares of Scilex stock in a transaction on Friday, May 17th. The shares were bought at an average cost of $0.90 per share, for a total transaction of $51,750.00. Following the acquisition, the director now directly owns 102,500 shares of the company’s stock, valued at approximately $92,250. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Scilex news, insider Jaisim Shah acquired 83,061 shares of the business’s stock in a transaction that occurred on Thursday, May 16th. The shares were bought at an average cost of $0.84 per share, with a total value of $69,771.24. Following the completion of the acquisition, the insider now directly owns 98,943 shares in the company, valued at approximately $83,112.12. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Jay Chun bought 57,500 shares of the stock in a transaction on Friday, May 17th. The shares were bought at an average price of $0.90 per share, with a total value of $51,750.00. Following the acquisition, the director now owns 102,500 shares of the company’s stock, valued at $92,250. The disclosure for this purchase can be found here. Insiders own 8.73% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Collective Family Office LLC boosted its position in Scilex by 68.4% during the first quarter. Collective Family Office LLC now owns 21,950 shares of the company’s stock valued at $35,000 after purchasing an additional 8,918 shares in the last quarter. Cannon Global Investment Management LLC bought a new stake in shares of Scilex in the 1st quarter valued at about $40,000. Focus Financial Network Inc. ADV bought a new stake in shares of Scilex in the 4th quarter valued at about $58,000. Bank of New York Mellon Corp purchased a new position in shares of Scilex in the 3rd quarter worth approximately $68,000. Finally, Donald L. Hagan LLC raised its stake in shares of Scilex by 49.1% during the 4th quarter. Donald L. Hagan LLC now owns 52,343 shares of the company’s stock worth $107,000 after acquiring an additional 17,245 shares in the last quarter. 69.67% of the stock is currently owned by hedge funds and other institutional investors.

About Scilex

Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.